CO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company, announced that it will release its first quarter 2022 financial results on May 12, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company, announced that it will release its first quarter 2022 financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. EDT to discuss these results with analysts and investors. Key management, including CEO Dwight Egan and CFO Brian Brown, will participate in the call. The call will be accessible via the company's website and will also be recorded for later viewing.
Details
News Market Reaction – CODX
The recorded move for CODX in the trading session of this news was +0.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, April 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2022 results on Thursday, May 12, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations.
The call and webcast will be available via:
Webcast: | ir.codiagnostics.com on the Events & Webcasts page |
Conference Call: | 877-317-6789 (domestic) or 412-317-6789 (international) |
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures, and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-first-quarter-2022-earnings-release-date-and-webcast-301535166.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.